WSTAM
PTCT icon

Wilbanks Smith & Thomas Asset Management’s PTC Therapeutics PTCT Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-175
Closed -$8K – 1068
2018
Q3 		$8K Buy
+175
New +$7.24K ﹤0.01% 1104

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's PTCT Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of PTC Therapeutics (PTCT) in Q4 2018, closing a stake of 175 shares — an estimated $8K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in PTCT in Q3 2018 and held it in 1 quarter. The position peaked at $8K in Q3 2018. 164 funds tracked by Wall St. Rank hold PTCT as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining PTC Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 175 PTC Therapeutics shares in Q4 2018, an estimated $8K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in PTC Therapeutics in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's PTC Therapeutics position peaked at $8K in Q3 2018.
  • 164 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.